<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554043</url>
  </required_header>
  <id_info>
    <org_study_id>SHR7280-103</org_study_id>
    <nct_id>NCT04554043</nct_id>
  </id_info>
  <brief_title>The PK/PD Study of SHR7280 Tablets in Healthy Subjects.</brief_title>
  <official_title>A Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of SHR7280 Tablets in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety, tolerability, pharmacokinetics&#xD;
      and pharmacodynamics of SHR7280 tablets in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GNRH antagonists can be used to treat sex hormone-dependent diseases, and SHR7280 is an oral&#xD;
      GNRH antagonist. The purpose of this study is to observe the safety, tolerability,&#xD;
      pharmacokinetics and pharmacodynamics of multiple oral doses of SHR7280 in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Actual">September 28, 2021</completion_date>
  <primary_completion_date type="Actual">September 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse events</measure>
    <time_frame>Pre-dose to 28±2 days after dose administration</time_frame>
    <description>Part 1 and Part 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUCτ) after the first dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit( 28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) after the first dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (Tmax) after the first dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to elimination half-life (T1/2) ;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total clearance(CL/F) of the drug from plasma after last morning dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution(Vz/F) after last morning dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) after last morning dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed serum concentration (Tmax) after last morning dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) after last morning dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Factor（Racc）after last morning dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUCτ) after last morning dose of SHR7280;</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine Parameters: Testosterone</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine Parameters: Estuarial</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine Parameters:Progesterone</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine Parameters: Luteinizing hormone</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine Parameters: Follicle stimulating hormone</measure>
    <time_frame>At pre-defined intervals from initial dose through final study visit (28±2 days after dose administration)</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>SHR7280 dose 1(male)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 14 days,Phase I(PART 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 2(male)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 14 days,Phase I(PART 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 3(male)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 14 days,Phase I(PART 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 4(male)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 14 days,Phase I(PART 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 5(male)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 14 days,Phase I(PART 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 1(female)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 21 days,Phase I(PART 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 2(female)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 21 days,Phase I(PART 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 3(female)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 21 days,Phase I(PART 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 4(female)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 21 days,Phase I(PART 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 6(male)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 14 days,Phase I(PART 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR7280 dose 7(male)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration for 14 days,Phase I(PART 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR7280</intervention_name>
    <description>treatment</description>
    <arm_group_label>SHR7280 dose 1(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 1(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 2(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 2(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 3(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 3(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 4(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 4(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 5(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 6(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 7(male)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>blank control</description>
    <arm_group_label>SHR7280 dose 1(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 1(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 2(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 2(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 3(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 3(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 4(female)</arm_group_label>
    <arm_group_label>SHR7280 dose 4(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 5(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 6(male)</arm_group_label>
    <arm_group_label>SHR7280 dose 7(male)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PART 1:&#xD;
&#xD;
          1. Healthy males , aged 18-65;&#xD;
&#xD;
          2. BMI 18 ~ 30 kg/m2;&#xD;
&#xD;
          3. Subjects in general good health. No clinically significant findings in Physical&#xD;
             examination and auxiliary examination.&#xD;
&#xD;
        PART 2:&#xD;
&#xD;
          1. premenopausal females, aged 18-45;&#xD;
&#xD;
          2. BMI 18 ~ 30 kg/m2;&#xD;
&#xD;
          3. Subjects in general good health. No clinically significant findings in Physical&#xD;
             examination and auxiliary examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        PART 1&#xD;
&#xD;
          1. Testosterone (T) &lt; 12 nmol/L;&#xD;
&#xD;
          2. ALT or AST or total bilirubin exceeds the upper limit of normal;&#xD;
&#xD;
          3. Those with positive nicotine test and alcohol breath test before administration, and&#xD;
             those with positive drug screening before administration;&#xD;
&#xD;
          4. Use of any medication within 1 month before administration; or use of medication that&#xD;
             does not exceed 5 half-lives, whichever is longer;&#xD;
&#xD;
          5. Subjects with chronic diseases or serious diseases that affect drug absorption,&#xD;
             distribution, metabolism and excretion;&#xD;
&#xD;
          6. Blood donation or donation of blood components within 1 month before screening, or&#xD;
             loss of blood equivalent to at least 200 mL, or transfusion within 2 months;&#xD;
&#xD;
          7. Use of GnRH agonists and GnRH antagonists within 6 months before screening and use of&#xD;
             any androgens and antiandrogens within 5 half-lives before screening;&#xD;
&#xD;
          8. Subjects with severe infection, severe trauma or major surgery within 6 months before&#xD;
             screening;&#xD;
&#xD;
          9. Positive results of infectious disease screening .&#xD;
&#xD;
         10. Allergic constitution or allergy to two or more kinds of food and drugs, including&#xD;
             known history of allergy to the study drug or any component of the study drug.&#xD;
&#xD;
        PART 2:&#xD;
&#xD;
          1. Pregnant or breast feeding;&#xD;
&#xD;
          2. FSH≥25U/L;&#xD;
&#xD;
          3. Positive serum pregnancy test (serum β-HCG test) result;&#xD;
&#xD;
          4. Abnormal uterine bleeding within 3 months prior to screening&#xD;
&#xD;
          5. ALT or AST or total bilirubin exceeds the upper limit of normal;&#xD;
&#xD;
          6. Those with positive nicotine test and alcohol breath test before administration, and&#xD;
             those with positive drug screening before administration;&#xD;
&#xD;
          7. Use of any medication within 1 month before administration; or use of medication that&#xD;
             does not exceed 5 half-lives, whichever is longer;&#xD;
&#xD;
          8. Subjects with chronic diseases or serious diseases that affect drug absorption,&#xD;
             distribution, metabolism and excretion;&#xD;
&#xD;
          9. Blood donation or donation of blood components within 1 month before screening, or&#xD;
             loss of blood equivalent to at least 200 mL, or transfusion within 2 months;&#xD;
&#xD;
         10. GnRH agonist use 6 months prior to Screening and GnRH antagonist or any sex hormone&#xD;
             use 2 months prior to Screening.&#xD;
&#xD;
         11. Subjects with severe infection, severe trauma or major surgery within 6 months before&#xD;
             screening&#xD;
&#xD;
         12. Positive results of infectious disease screening .&#xD;
&#xD;
         13. Allergic constitution or allergy to two or more kinds of food and drugs, including&#xD;
             known history of allergy to the study drug or any component of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Cao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Qingdao University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shan Dong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Hengrui shall own the exclusive rights to all results, data, findings, radiological &amp; diagnostic images, discoveries, inventions &amp; specifications, whether patentable or not, that are originated, conceived, derived, produced, discovered, invented or otherwise made by Center, PI and/or Study Team Physicians and/or Members in connection with the performance of the Study (i.e. Results).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

